Last Updated on February 12, 2020 by Chris Stang
Financial Health Score
Our Financial Health Score is designed to specifically measure the financial health of developing biotechnology companies. As we looked around at other scoring systems or ranks, we were constantly confronted with the realization that these scores were not applicable to biotechnology. How and why should the same score be used to assess the financial health of developing mid-cap biotechnology companies as mega-cap technology companies? They should not! This is why we diligently created this proprietary measure of financial health. Our proprietary score incorporates important considerations for clinical stage biotechnology companies such as cash runway, debt, and current cash position, among other inputs relevant to developing biotechnology companies.
Our scale ranges from negative five up to a score of twenty-four. Interpretation is as follows:
- Score of 15.1 to 24 [A]: These companies are the cream of the crop from a financial standpoint based on our proprietary score. There is a strong financial set-up for these companies to develop their clinical assets.
- Score of 10.2 to 15 [B]: These companies have very favorable financial scores. There is limited concern from a financial standpoint.
- Score of 5.1 to 10 [C]: Companies in this tier have an average financial score. Companies are not expected to be as high risk as those with lower scores, but have characteristics that warrant careful evaluation.
- Score of -5 to 5 [D]: The lowest tier on our financial score. These companies have a concerning financial situation which warrants careful evaluation of risks.
Pipeline Score
Our Pipeline Score objectively measures a biotechnology company’s clinical pipeline. Taking into account the number of candidates, the number of indications, the stage of development, and rights to the candidates in key markets, our score will range from -5 to 24, with a higher score representing a stronger score. Companies with lower scores may be due to a limited number of candidate, limited number of indications, or lack of rights to future revenue generated (licensing deals).
| Company Ticker | Company Name | Financial Score | Pipeline Score |
| ACST | Acasti Pharma | 1.38 | -0.70 |
| ADMA | ADMA Biologics | 3.23 | -5.00 |
| ADRO | Aduro BioTech | 10.35 | 0.48 |
| ADVM | Adverum Biotechnologies | 14.86 | -3.62 |
| ADXS | Advaxis | 13.12 | -0.56 |
| AGIO | Agios Pharmaceuticals | 12.19 | 24.00 |
| ALBO | Albireo Pharma | 12.48 | 5.59 |
| AMRN | Amarin Corporation | 11.92 | -5.00 |
| APVO | Aptevo Therapeutics | 2.32 | -3.62 |
| ARWR | Arrowhead Pharmaceuticals | 12.42 | 1.61 |
| AVEO | AVEO Oncology | 6.24 | 8.91 |
| AXGT | Axovant Gene Therapies | 2.67 | 2.77 |
| AYTU | Aytu Bioscience | 5.19 | ^ |
| BCRX | BioCryst Pharmaceuticals | 4.81 | 4.66 |
| BLCM | Bellicum Pharmaceuticals | 9.04 | 1.71 |
| BLUE | bluebird bio | 13.85 | 10.02 |
| CALA | Calithera Biosciences | 11.67 | 15.72 |
| CFMS | ConforMIS | 7.59 | ^ |
| CLDX | Celldex Therapeutics | 11.79 | 1.58 |
| CLLS | Cellectis | 15.11 | 0.54 |
| CLVS | Clovis Oncology | 6.21 | 8.36 |
| CPRX | Catalyst Pharmaceuticals | 12.27 | -1.89 |
| CRSP | Crispr Therapeutics | 13.27 | 2.21 |
| CTMX | CytomX Therapeutics | 10.80 | 1.65 |
| DMPI | DelMar Pharmaceuticals | 8.36 | 0.43 |
| EDIT | Editas Medicine | 9.7 | -2.78 |
| EOLS | Evolus | 4.5 | ^ |
| EPZM | Epizyme | 16.51 | 13.72 |
| EXEL | Exelixis | 12.50 | 9.65 |
| EYPT | Eyepoint Pharmaceuticals | 3.0 | -0.70 |
| FLXN | Flexion Therapeutics | 9.36 | 3.33 |
| FPRX | Five Prime Therapeutics | 13.32 | 3.81 |
| GALT | Galectin Therapeutics | 17.63 | 3.65 |
| GLMD | Galmed Pharmaceuticals | 16.76 | -0.70 |
| IMGN | ImmunoGen | 13.05 | 6.08 |
| IMMU | Immunomedics | 10.70 | 11.13 |
| INO | Inovio Pharmaceuticals | 7.17 | Coming Soon |
| KALA | Kala Pharmaceuticals | 11.95 | -0.82 |
| KRYS | Krystal Biotech | 18.81 | 0.08 |
| LCTX | Lineage Cell Therapeutics | 9.39 | 1.30 |
| LJPC | La Jolla Pharmaceutical Company | 4.87 | -0.70 |
| MGNX | MacroGenics | 12.48 | 13.48 |
| MRNA | Moderna | 12.55 | 12.43 |
| MRTX | Mirati Therapeutics | 15.35 | 5.74 |
| MTNB | Matinas BioPharma | 14.60 | 2.23 |
| NDRA | ENDRA Life Sciences | 1.59 | ^ |
| NEO | NeoGenomics | 11.95 | ^ |
| NGM | NGM Biopharmaceuticals | Coming Soon | 1.43 |
| NNVC | NanoViricides | 6.66 | -5.00 |
| NVAX | Novavax | 8.37 | 8.99 |
| NK | Nantkwest | 14.61 | 2.28 |
| OCUL | Ocular Therapeutix | 4.87 | 4.70 |
| OVID | Ovid Therapeutics | 11.31 | 4.45 |
| PBYI | Puma Biotechnology | 11.19 | 6.73 |
| PRTK | Paratek Pharmaceuticals | 9.16 | -0.92 |
| PTI | Proteostasis Therapeutics | 13.68 | 3.23 |
| PTLA | Portola Pharmaceuticals | 5.93 | 5.09 |
| QURE | Uniqure | 13.31 | -0.70 |
| RARE | Ultragenyx Pharmaceutical | 15.96 | 2.97 |
| RCKT | Rocket Pharmaceuticals | 14.01 | 0.29 |
| RGNX | Regenxbio | 16.84 | 6.75 |
| SAVA | Cassava Sciences | 16.98 | -2.26 |
| SCYX | SCYNEXIS | 10.48 | 9.07 |
| SESN | Sesen Bio | 7.43 | 1.48 |
| SGMO | Sangamo Therapeutics | 10.96 | 8.24 |
| TGTX | TG Therapeutics | 3.09 | 17.57 |
| TRVN | Trevena | 9.68 | 1.30 |
| VBIV | VBI Vaccines | 5.91 | 5.53 |
| VKTX | Viking Therapeutics | 18.90 | 2.79 |
| VSTM | Verastem | 7.33 | 6.60 |
| XLRN | Acceleron Pharma | 18.32 | 2.15 |
| ZYNE | Zynerba Pharmaceuticals | 16.48 | 14.33 |
^The pipeline score was developed for assessment of drug candidates and is not applicable to diagnostic, surgical companies, or fully commercialized companies.